Heparin in the Treatment of Cerebral Venous Thrombosis.
From: Department of Medicine (Neurology), Aga Khan University Medical College, Karachi.
JPMA. The Journal of the Pakistan Medical Association
- Publish Date: Nov 2006
- ISSN: 0030-9982
- Volume: 56
- Issue: 11
- Pages: 541-3
- Medium: Print
- Language: English
- Citation (JAMA): Shafqat Saad, Kamal Ayeesha K, Wasay Mohammad, et al. Heparin in the Treatment of Cerebral Venous Thrombosis.. Nov 2006;56:541-3
Abstract
Cerebral venous thrombosis (CVT) is a potentially life-threatening condition requiring rapid diagnosis and urgent treatment. Heparin anticoagulation is the time-honoured treatment, and is advocated in all cases of CVT, irrespective of etiology or presence of haemorrhage. The supportive evidence is largely observational; data from randomized placebo-controlled trials shows a nonsignificant trend favouring heparin. Current practice is to begin heparin (unfractionated or low-molecular weight) immediately on confirmation of the diagnosis. Newer antithrombotic agents such as ximelagatran may offer advantages over heparin and need to be investigated in the treatment of CVT.
Mesh Headings (Keywords): Anticoagulants, Cerebral Veins, Heparin, Humans, Intracranial Thrombosis, Risk Factors, Sinus Thrombosis, Intracranial, Thrombolytic Therapy, Venous Thrombosis
Check for Full Text / PubMed Unique Identifier (PMID): 17183987
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.